A Single-Center Experience and Literature Review of Management Strategies for Infection in Hematopoietic Stem Cell Transplant Patients

Overview

Journal Infect Dis Clin Pract (Baltim Md)

Specialty Infectious Diseases

Date 2021 Jan 11

PMID 33424210

Citations 3

Authors

Aneela Majeed

Marti M Larriva

Ahmad Iftikhar

Adeela Mushtaq

Patrick Campbell

Mustafa Nadeem Malik

Abdul Rafae

Muhammad Abu Zar

Ahmad Kamal

Midhat Lakhani

Nageena Rani Khalid

Tirdad T Zangeneh

Faiz Anwer

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of our study is to evaluate risk factors associated with the development of infection (CDI) in hematopoietic stem cell transplant (HSCT) patients, determine its incidence and report outcomes of CDI in our patient population.

Methods: We performed a retrospective review of medical records of adult HSCT recipients diagnosed between 2013 and 2016 at our center. Logistic regression models were used to determine the relationship between risk factors and the odds of CDI.

Results: The overall incidence of CDI in HSCT patients was 9.4%. The incidence of CDI was higher in allogeneic HSCT (20%) versus autologous HSCT (4.8%). No statistically significant differences in age, gender, cancer type, transplant type were found between those who developed CDI and those who did not. However, patients with CDI had a longer length of stay (25 days) and used more antibiotics (30 days prior to and during admission for HSCT) than non-CDI patients (19 days). Only two of 17 patients (11.8%) with CDI experienced recurrence among 180 patients after HSCT. No patient suffered from toxic megacolon or ileus and no patient underwent colectomy. There was no mortality associated with CDI at our center.

Conclusion: CDI has an incidence rate of 9.4% in HSCT recipients. Established risk factors including age, gender, cancer type, and transplant type were not identified as risk factors in our population. However, longer LOS and use of greater than four lines of antibiotics were observed among those with CDI compared to those without CDI.

Citing Articles

Epidemiology and Outcomes of Recurrent Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.

Sanchez E, Krantz E, Kassamali Escobar Z, Tverdek F, Rosen E, Ueda Oshima M Open Forum Infect Dis. 2024; 11(10):ofae570.

PMID: 39450393 PMC: 11500450. DOI: 10.1093/ofid/ofae570.

Determination of Risk Factors for Infectious Diarrhea in Patients with Hematological Malignancy.

Sahinkaya S, Ture Z, Unal A, Unuvar G, Kilic A Infect Chemother. 2024; 56(2):239-246.

PMID: 38403877 PMC: 11224029. DOI: 10.3947/ic.2023.0102.

Prevalence of Infection in the Hematopoietic Transplantation Setting: Update of Systematic Review and Meta-Analysis.

Luo Y, Zhang S, Shang H, Cui W, Wang Q, Zhu B Front Cell Infect Microbiol. 2022; 12:801475.

PMID: 35265530 PMC: 8900492. DOI: 10.3389/fcimb.2022.801475.

References

Kyne L, Warny M, Qamar A, Kelly C . Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000; 342(6):390-7. DOI: 10.1056/NEJM200002103420604. View

Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C . Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005; 128(3):764-70. DOI: 10.1053/j.gastro.2004.11.004. View

Scardina T, Kang Martinez E, Balasubramanian N, Fox-Geiman M, Smith S, Parada J . Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients. Pharmacotherapy. 2017; 37(4):420-428. DOI: 10.1002/phar.1914. View

Boyle N, Magaret A, Stednick Z, Morrison A, Butler-Wu S, Zerr D . Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob Resist Infect Control. 2015; 4:41. PMC: 4606905. DOI: 10.1186/s13756-015-0081-4. View

Lee Y, Arguello E, Jenq R, Littmann E, Kim G, Miller L . Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. J Infect Dis. 2017; 215(7):1117-1123. PMC: 5426375. DOI: 10.1093/infdis/jix011. View

McDonald L, Gerding D, Johnson S, Bakken J, Carroll K, Coffin S . Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66(7):e1-e48. PMC: 6018983. DOI: 10.1093/cid/cix1085. View

Zar F, Bakkanagari S, Moorthi K, Davis M . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45(3):302-7. DOI: 10.1086/519265. View

Cozar-Llisto A, Ramos-Martinez A, Cobo J . Clostridium difficile Infection in Special High-Risk Populations. Infect Dis Ther. 2016; 5(3):253-69. PMC: 5019980. DOI: 10.1007/s40121-016-0124-z. View

FEKETY R, McFarland L, Surawicz C, Greenberg R, Elmer G, Mulligan M . Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997; 24(3):324-33. DOI: 10.1093/clinids/24.3.324. View

10.

Spadao F, Gerhardt J, Guimaraes T, Dulley F, de Almeida Junior J, Batista M . Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. Rev Inst Med Trop Sao Paulo. 2014; 56(4):325-31. PMC: 4131819. DOI: 10.1590/s0036-46652014000400010. View

11.

Drekonja D, Butler M, MacDonald R, Bliss D, Filice G, Rector T . Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011; 155(12):839-47. DOI: 10.7326/0003-4819-155-12-201112200-00007. View

12.

Greenberg R, Marbury T, Foglia G, Warny M . Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine. 2012; 30(13):2245-9. DOI: 10.1016/j.vaccine.2012.01.065. View

13.

Hsu J, Abad C, Dinh M, Safdar N . Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010; 105(11):2327-39. DOI: 10.1038/ajg.2010.254. View

14.

Dubberke E, Sadhu J, Gatti R, Reske K, Dipersio J, Devine S . Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol. 2007; 28(2):208-11. DOI: 10.1086/511792. View

15.

Wilcox M, Gerding D, Poxton I, Kelly C, Nathan R, Birch T . Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017; 376(4):305-317. DOI: 10.1056/NEJMoa1602615. View

16.

Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

17.

Samore M, DeGirolami P, Tlucko A, Lichtenberg D, Melvin Z, Karchmer A . Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994; 18(2):181-7. DOI: 10.1093/clinids/18.2.181. View

18.

Pilcante J, Rojas P, Ernst D, Sarmiento M, Ocqueteau M, Bertin P . Clostridium difficile infection in Chilean patients submitted to hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2015; 37(6):388-94. PMC: 4678790. DOI: 10.1016/j.bjhh.2015.07.010. View

19.

Kamboj M, Xiao K, Kaltsas A, Huang Y, Sun J, Chung D . Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant. 2014; 20(10):1626-33. PMC: 4852556. DOI: 10.1016/j.bbmt.2014.06.025. View

20.

Arango J, Restrepo A, Schneider D, Callander N, Ochoa-Bayona J, Restrepo M . Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006; 37(5):517-21. DOI: 10.1038/sj.bmt.1705269. View